This document discusses cancer immunotherapy. It begins by describing tumor antigens that can be recognized by the immune system, such as tumor-specific antigens, tumor-associated antigens, and antigens from oncogenic viruses. It then discusses how tumors evade the immune system and various approaches to immunotherapy, including active immunotherapies using vaccines made of tumor cells, purified antigens, or antigen-loaded dendritic cells. Passive immunotherapies discussed include adoptive cellular therapy, monoclonal antibodies, and immunotoxins. Clinical trials and effectiveness of different immunotherapies are also summarized.
n overview of current immunotherapy therapies used to treat cancer. Also provides MOA of various medications, and updates on SITC guidelines for metastatice melanoma.
Therapeutic prospects in Cancer Immunotherapy.
Interleukins for Renal Cell Carcinoma.
BCG for Bladder Cancer.
Vaccination Strategies: Oncolytic virus for melanoma, Dendritic Cell therapy for CA Prostate.
Immune Checkpoint inhibitors. PD1 and PD L1 inhibitors.
Adoptive Cell Therpay. CAR T Cell Therapy
Clinical efficacy. Costs.
Types of immunotherapy
Oncology
cancer vaccines
adoptive T cell transfer
oncolytic viruses
monoclonal antibodies
cytokine
treatment of cancer with immunotherapy
n overview of current immunotherapy therapies used to treat cancer. Also provides MOA of various medications, and updates on SITC guidelines for metastatice melanoma.
Therapeutic prospects in Cancer Immunotherapy.
Interleukins for Renal Cell Carcinoma.
BCG for Bladder Cancer.
Vaccination Strategies: Oncolytic virus for melanoma, Dendritic Cell therapy for CA Prostate.
Immune Checkpoint inhibitors. PD1 and PD L1 inhibitors.
Adoptive Cell Therpay. CAR T Cell Therapy
Clinical efficacy. Costs.
Types of immunotherapy
Oncology
cancer vaccines
adoptive T cell transfer
oncolytic viruses
monoclonal antibodies
cytokine
treatment of cancer with immunotherapy
A detailed ppt about cancer immunotherapy.
includes:-
Immunosurveillance and Immunoediting
Dentritic cell vaccines
Antibody therapy
Combined therapy
immune blockades
Cytokine therapy
T cell therapy
Include latest research finding about therapy.
In this presentation, I discuss a new standard of treatment in cancers which is immunotherapy. I also discuss the few cancers for which it has been approved.
This presentation is part of MIU CE Pharmacy Program and is designed primarily for pharmacists with the following learning objectives:
1- Explain the mechanisms of action behind immune response to cancer and the application of immunotherapy in cancer treatment
2- Distinguish new and emerging immunotherapy classes and individual agents efficacy, safety to therapy in cancer treatment
3-Strategies to counsel and assist patients to overcome barriers to therapy, including Treatment side effects to improve adherence to therapy
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is being studied in the treatment of some types of cancer. Also called chimeric antigen receptor T-cell therapy.
chimeric antigen receptor, its structure and role in killing tumor cells,mechanism of antitumor killing, car's in clinic,evolution of cars and new chimeric antigen models
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...Michael Sheckler
These slides provide an overview of 100 therapeutic cancer vaccines in development, a look at some of the failures, what's been and is being done to address the clinical development of these vaccines and a snapshot of some deals, terms and the number of companies seeking commercializations partners.
A detailed ppt about cancer immunotherapy.
includes:-
Immunosurveillance and Immunoediting
Dentritic cell vaccines
Antibody therapy
Combined therapy
immune blockades
Cytokine therapy
T cell therapy
Include latest research finding about therapy.
In this presentation, I discuss a new standard of treatment in cancers which is immunotherapy. I also discuss the few cancers for which it has been approved.
This presentation is part of MIU CE Pharmacy Program and is designed primarily for pharmacists with the following learning objectives:
1- Explain the mechanisms of action behind immune response to cancer and the application of immunotherapy in cancer treatment
2- Distinguish new and emerging immunotherapy classes and individual agents efficacy, safety to therapy in cancer treatment
3-Strategies to counsel and assist patients to overcome barriers to therapy, including Treatment side effects to improve adherence to therapy
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is being studied in the treatment of some types of cancer. Also called chimeric antigen receptor T-cell therapy.
chimeric antigen receptor, its structure and role in killing tumor cells,mechanism of antitumor killing, car's in clinic,evolution of cars and new chimeric antigen models
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...Michael Sheckler
These slides provide an overview of 100 therapeutic cancer vaccines in development, a look at some of the failures, what's been and is being done to address the clinical development of these vaccines and a snapshot of some deals, terms and the number of companies seeking commercializations partners.
a short presentation about the types of treatments used in cancer therapy, including traditional chemotherapy, targeted therapy, immunotherapy and hormonal therapy. also a short talk about side effects and administration of the CTX drugs.
El 3 de noviembre de 2015, la Fundación Ramón Areces organizó en su sede en Madrid (C/ Vitruvio, 5) una jornada sobre ‘El cáncer como consecuencia del envejecimiento: posibles soluciones’. Coordinado por la investigadora María Vallet Regí, del Departamento de Química Inorgánica y Bioinorgánica de la Universidad Complutense de Madrid, contó con la presencia, entre otros científicos, de Mariano Barbacid, Lodovico Balducci y Theresa Guise.
The presentation outlines aspects of immunity against cancer, evasion strategies by cells, immunotherapy in cancer, cancer vaccines etc. Download and view the slideshow for better experience.
Prepared in Sept 2014
This presentation deals with the concept of Tumor immunity. It cover different types of Tumor and tumor antigens. How immunology plays role in tumor detection and diagnosis is also explained in this presentation. Concept of Tumor imunoprophylaxis and tumor immunotherapy is also explained.
Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Encryption in Microsoft 365 - ExpertsLive Netherlands 2024Albert Hoitingh
In this session I delve into the encryption technology used in Microsoft 365 and Microsoft Purview. Including the concepts of Customer Key and Double Key Encryption.
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Accelerate your Kubernetes clusters with Varnish CachingThijs Feryn
A presentation about the usage and availability of Varnish on Kubernetes. This talk explores the capabilities of Varnish caching and shows how to use the Varnish Helm chart to deploy it to Kubernetes.
This presentation was delivered at K8SUG Singapore. See https://feryn.eu/presentations/accelerate-your-kubernetes-clusters-with-varnish-caching-k8sug-singapore-28-2024 for more details.
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
Connector Corner: Automate dynamic content and events by pushing a buttonDianaGray10
Here is something new! In our next Connector Corner webinar, we will demonstrate how you can use a single workflow to:
Create a campaign using Mailchimp with merge tags/fields
Send an interactive Slack channel message (using buttons)
Have the message received by managers and peers along with a test email for review
But there’s more:
In a second workflow supporting the same use case, you’ll see:
Your campaign sent to target colleagues for approval
If the “Approve” button is clicked, a Jira/Zendesk ticket is created for the marketing design team
But—if the “Reject” button is pushed, colleagues will be alerted via Slack message
Join us to learn more about this new, human-in-the-loop capability, brought to you by Integration Service connectors.
And...
Speakers:
Akshay Agnihotri, Product Manager
Charlie Greenberg, Host
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
Epistemic Interaction - tuning interfaces to provide information for AI supportAlan Dix
Paper presented at SYNERGY workshop at AVI 2024, Genoa, Italy. 3rd June 2024
https://alandix.com/academic/papers/synergy2024-epistemic/
As machine learning integrates deeper into human-computer interactions, the concept of epistemic interaction emerges, aiming to refine these interactions to enhance system adaptability. This approach encourages minor, intentional adjustments in user behaviour to enrich the data available for system learning. This paper introduces epistemic interaction within the context of human-system communication, illustrating how deliberate interaction design can improve system understanding and adaptation. Through concrete examples, we demonstrate the potential of epistemic interaction to significantly advance human-computer interaction by leveraging intuitive human communication strategies to inform system design and functionality, offering a novel pathway for enriching user-system engagements.
7. TYPE OF ANTIGENS EXAMPLES OF HUMAN TUMOR
ANTIGENS
1 . PRODUCTS OF
ONCOGENES ,
TUMOR SUPPRESSOR
GENES
ONCOGENES- RAS MUTATION,
- p210 PRODUCT OF Bcr/Abl
REARRANGEMENTS,
- OVEREXPRESSED Her-2/neu
TSG- -MUTATED p53
2 .MUTANTS OF
CELLULAR
GENES NOT INVOLVED
IN TUMORIGENESIS
-P19 A MUTATION IN MUTAGENIZED MURINE
MASTOCYTOMA
3.PRODUCTS OF GENES
THAT ARE SILENT IN MOST
NORMAL TISSUES.
MAGE,BAGE,GAGE PROTEINS EXPRESSED IN
MELANOMAS AND MANY CARCINOMAS
4.PRODUCTS OF
OVEREXPRESSED
GENES
TYROSINASE,
gp100,
MART IN MELANOMAS
8. TYPE OF ANTIGENS EXAMPLES OF HUMAN TUMOR
ANTIGENS
5.PRODUCTS OF
ONCOGENIC VIRUSES
-PAPILLOMAVIRUS E6 AND E7 PROTEINS (CERVICAL
CARCINOMAS)
-EBNA-1 PROTEIN OF EBV
-SV40 (SV40-INDUCED RODENTS TUMORS)
-HTLV-1
6.ONCOFETAL ANTIGENS -CEA ON MANY TUMORS
-ALPHA-FETOPROTEIN.(AFP)
7.GLYCOLIPIDS
&GLYCOPROTEINS
GM-2,GD-2 ON MELANOMAS
CA-125 & CA-19-9,ovarian cancer
MUC-1-breast cancer
8.DIFFERENTIATION
ANTIGENS NORMALLY
PRESENT IN TISSUE OF
ORIGEN
-PROSTATE SPECIFIC ANTIGEN
-MARKERS OF LYMPHOCYTES: CD-10,CD -20
Ig IDIOTYPES ON B-CELLS
11. [2] ANTIBODIES
TUMOR BEARING HOST MAY PRODUCE Abs AGAINST VARIOUS TUMOR Ags .
eg:-EBV ASSOCIATED LYMPHOMAS HAVE SERUM Abs AGAINST EBV –
ENCODED Ag EXPRESSED ON THE SURFACE OF THE LYMPHOMA CELLS
Abs MAY ACTIVATE COMPLEMENT SYSTEM OR KILL TUMOR CELLS BY ADCC
12. Chediak-Higashi syndrome NK cell impairment increased
incidence of certain types of tumour
NK cells release TNF- + NK cytotxic factor
Mechanism-ADCC-Fcγ III
Activity increased by IL-2 & IL-12,INF’s
capable of lysing a wide variety of tumour cells”.
Respond to low level of MHC I
[3] NK CELLS
17. Tumour cell present
Broken up to
release antigens
APC
APC recruits T cells
able to recognise
tumour antigens
T
T
Th
CTL
CTL recognise
and destroy other
tumour cells
CTL
Th cells educate
other T/B cells
B
Ab / ADCC /
cytokine attack
21. S.No
.
Type of vaccine Vaaccine
preparation
Animal model Clinical trials
4. Cytokine & co-
stimulator
enhanced
vaccines
•Tumor cells
transfected with
cytokine or B-7 genes
•APCs transfected
with cytokine +tumor
antigens
•Renal cancer,
sarcoma,B-cell
leukemia,
lung cancer
Melanoma
Sarcoma
& others
Melanoma,
renal cancer
& others
5. DNA vaccine Immunoglobulin with
plasmid encoding
tumor antigens
Melanoma Melanoma
6. Viral vector •Adenovirus vaccine
•Virus encoding
tumor antigens
+ cytokines
•Melanoma
•sarcoma
•Melanoma
• Melanoma
22.
23. IMMUNOTHERAPY WITH GENE TRANSFECTED TUMOR CELLS
S.No. Cytokine Tumor
rejection
in animals
Inflammatory
infiltrate
Immunity
against
parental tumor
(animal model)
Clinical
trials
1. IL-2 YES;
mediated
by T- cell
Lymphocytes
neutrophils
In some cases
of renal
cancer,
melanoma
Renal
cancer,
melanoma
2. Il-4 yes Eosinophil ,
macrophages
No long lasting
immunity in
human trials
Melanoma
Renal
cancer
3. INF-γ Variable Macrophages,
Other cells
sometimes
4. TNF variable Neutrophils &
lymphocytes
No
5. GM-CSF yes Macrophages,
Other cells
Yes(long lived
T-cell immunity)
Renal
cancer
6. Il-2 sometimes Macrophages,
Other cells
Sometimes
24. S.No CYTOKINE TUMOR
REJECTION IN
ANIMALS
CLINICAL TRIALS TOXICITY
1. IL-2 YES Melanoma,renal cancer
,colon cancer,limited
success
Vascular
leak,shock,
pulmonary
edema
2. TNF Only with
local
administratio
n
Sarcoma,melanoma Septic syndrome
3. Il-12 YES, Variable Toxicity trials (phase I) in
melanoma,others
Abnormal liver
fuction
4. IL-6 Melanoma Renal cancer Fever ,liver,&CNS
toxicity,hyperte-
sion
5. GM-CSF NO In routine use to promote
bone marrow rcovery
Bone pain
SYSTEMIC CYTOKINE THERAPY FOR TUMORS
30. • Adminstration of monoclonal antibodies which target either tumour-
specific or over-expressed antigens.
• Kill tumour cells in a variety of ways:
Apoptosis
induction
Complement-
mediated
cytotoxicity
ADCC
NKMØ
Conjugated to
toxin / isotope
31.
32. Complete regression of a
large liver metastasis from
kidney cancer in a patient
treated with IL-2.
Regression is ongoing
seven years later
Effective therapies
Rosenberg (2001) Nature, 411;381-4
33. Name Malignancy Target
Rituxan B cell lymphoma CD20
Herceptin Breast, lymphoma Her-2/neu
Campath B-CLL CD52
Erbitux Colo-rectal EGFR
Avastin Colo-rectal VEGF
Mylotarg AML CD33
(calicheamicin)
Bexxar B cell lymphoma CD20
(131In / 90Y)
34. Effectiveness of multiple antigen vaccines
Patient with multiple metastatic melanomas
treated with tyrosinase / gp100 / MART vaccine
35. Advances in immunotherapy
chimeric molecules→immune-stimulatory cytokine +antibody →
targets the cytokine's activity to a specific environment such as
tumor →destroying the cancer-causing cells without the unwanted
side-effects
•On Wednesday 7 September 2011 Scientists in Singapore suggested
antibody-based therapies can be used to target proteins inside cancer
cells.
•Mechanism of Ab entering the cell is not known. It will be the subject
of future research.
• An interesting recent variation on the idea of boosting host immune
responses against tumors is to eliminate normal inhibitory signals for
lymphocytes.
•In some animal models, blocking the inhibitory T cell receptor CTLA-4
has led to strong immune responses against transplanted tumors.
Editor's Notes
Cancer is a major health problem worldwide. It is most important cause of morbidity and mortality. Cancer arises from the uncontrolled growth proliferation and spread of clones of transformed cells.Cancer cells are self altered cells that have escaped normal growth-regulating mechanism.Although various immune responses can be generated to tumor cells, the response frequently is not sufficient to prevent tumor growth. One approach to cancer treatment is to augment or supplement these natural defense mechanisms.
IMMUNE SURVEILLANCE THEORY- The immune surveillance theory was first conceptualized in the early 1900s by Paul Ehrlich. He suggested that cancer cells frequently arise in the body but are recognized as foreign and eliminated by the immune system. Some 50 years later, Lewis Thomas suggested that the cell-mediated branch of the immune system had evolved to patrol the body and eliminate cancer cells.In 1950 Macfarlane Burnet proposed immune surveillance ,according to which a physiologic function of the immune system is to recognize & destroy clones of transformed ells before they grow into tumors and to kill tumors after they formedAccording to these concepts, tumors arise only if cancer cells are able to escape immune surveillance, either by reducing their expression of tumor antigens or by an impairment in the immune response to these cells.
IMMUNE RESPONSE FREQUENTLY FAIL TO PREVENT THE TUMOR GROWTH DUE TO Resemblance of tumor cells to with host cells. Most tumors express only a few antigens that may be recognised as non-self and as a result, most tumors tend to be weekly immunogenic. Tumors induced by oncogenic viruses & potent carcinogens are able to elicit strong immune response.Rapid growth & spread of tumors may overwhelm the capacity of the immune system to eradicate tumor requires that all the malignant cells be eliminated.Many tumors have specialised mechanism for evading host immune response.
May be expressed on foetal cellsShared by normal and tumor cells.{Tumor-associated developmental Ag (TADA)},but not adult cells.Unique to a tumor. Very difficult to detectPlay an important role in tumor rejection. Oncogenic mutants of normal cellular genes:ras, bcr-abl, p53Randomly mutated genes: TSTA‘s (tumor-specific transplantation antigens)Can be identified: biochemical cDNA cloning
Types of tumor antigens recognized by T cells. Tumor antigens that are recognized by tumor-specific CD8*T cells may be mutated forms of normal self proteins, products of oncogenes or tumor suppressor genes, over-expressed or aberrantly expressed self proteins, or products of oncogenic viruses. Tumor antigens may also be recognized by CD4* T cells, but less is known about the role that CD4* T cells play in tumor immunity. EBNA -Epstein-Barr virus nuclear antigen.
FIG-3:-Induction of CD8* T cell responses against tumors. CD8* T cell responses to tumors may be induced by cross-priming (also called cross-presentation), in which the tumor cells and/or tumor antigens are taken up by professional APCs, processed, and presented to T cells. In some cases, B7 co-stimulators expressed by the APCs provide the second signals for the differentiation of the CD8* T cells. The APCs may also stimulate CD4* helper T cells, which provide the second signals for CTL developmentDifferentiated CTLs kill tumor cells without a requirement for co-stimulation or T cell help.